A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients (ETOS)

AstraZeneca

Status: Completed

Conditions: Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT00999895

NIS-NGR-DUM-2009/1

Details and patient eligibility

About

The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).

Enrollment: 574 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of schizophrenia (as per DSM-IV), at least 6 months prior to enrolment in the study
• Subjects who have initiated a new antipsychotic treatment within the preceding 2 weeks
• Subjects whose prior and current antipsychotic treatment consists of any typical or atypical antipsychotic monotherapy

Exclusion criteria

• Subjects fulfilling criteria for diagnosis of any other psychiatric condition (except from schizophrenia), as per DSM-IV Axis Ι, concomitant organic mental disorder or mental retardation
• Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSM-IV criteria and not in full remission
• Female subjects who are pregnant or lactating

Trial design

574 participants in 1 patient group

Antipsychotic outpatients with schizophrenia

Description:

Switched treatment of antipsychotic outpatients with schizophrenia